Article

Suresh Ramalingam on Toxicities Associated With Immunotherapy in Different Disease Types

Author(s):

Suresh S. Ramalingam

Suresh S. Ramalingam, a professor of medical oncology at the Winship Cancer Institute of Emory University, comments on the difference in toxicities associated with immunotherapy.

Suresh S. Ramalingam, a professor of medical oncology at the Winship Cancer Institute of Emory University, comments on the difference in toxicities associated with immunotherapy.

Related Videos
Registered nurse Patricia Jakel emphasizes the importance of educating patients on evolving breast cancer research and the need for routine screenings.
Dr. Debu Tripathy highlights the importance of staying informed on breast cancer advancements and how this empowers patients to make informed decisions.
Image od grey haired Doctor.
Antibody-drug conjugates have had a tremendous impact on breast cancer care and treatment, according to Dr. Charles E. Geyer.
Dr. Emre Yekedüz highlighted strategies that may improve patients' quality of life and mitigate treatment-related side effects in renal cell carcinoma.
Image of man with grey hair.
Image of man with black hair.
Image of doctor with grey hair.
Image of doctor with black hair.
Related Content
Orca-T improved survival free of moderate-to-severe cGVHD across leukemia subtypes: © nobeastsofierce - stock.adobe.com.
March 18th 2025

Orca-T Doubles Graft-Versus-Host Disease-Free Survival in Leukemia

Spencer Feldman
Treatment with the T-cell immunotherapy Orca-T improved survival free of moderate-to-severe chronic graft-versus-host disease across leukemia subtypes.
cancer horizons podcast logo: a white microphone on a blue background
March 4th 2024

Cannabis Talks During Cancer, Cardiometabolic Comorbidities and Current Research

Alex Biese Brielle Benyon
In addition to a breakthrough therapy designation for a lung cancer drug, this week we’ll be talking a lot about additional side effects and health conditions that may come with a cancer diagnosis, and how to manage them.
green background with white text indicating FDA Approval, What You Need to Know
March 8th 2025

FDA Approves Biosimilars for Cancer-Related Skeletal Events

Alex Biese
The FDA has approved Stoboclo and Osenvelt to address skeletal issues faced by patients with cancer.
CURE Cancer Horizons logo
February 26th 2024

FDA Approvals from February 2024

Alex Biese Brielle Benyon
February brought in multiple FDA approvals in the oncology space. Here’s an overview of some of the most recent ones.
Researchers have found an association between the use of ICIs for cancer treatment and a risk of new onset psoriasis: © Dragana Gordic - stock.adobe.com
March 3rd 2025

Immune Checkpoint Inhibitors For Cancer Associated With Psoriasis Risk

Alex Biese
Researchers have discovered a strong association between the use of immune checkpoint inhibitors for cancer treatment and a risk of new onset psoriasis.
Fractionated reirradiation is safe and feasible in patients with recurrent high-grade glioma; © My Ocean Studio - stock.adobe.com
February 27th 2025

Fractionated Reirradiation is Safe and Feasible in High-Grade Glioma

Ryan Scott
Fractionated reirradiation is safe and feasible, suggesting higher reirradiation dose may be feasible in patients with recurrent high-grade glioma.